Printer Friendly

Nitto Medic to distribute Nicox's AdenoPlus acute conjunctivitis test in Japan.

M2 PHARMA-August 29, 2014-Nitto Medic to distribute Nicox's AdenoPlus acute conjunctivitis test in Japan

(C)2014 M2 COMMUNICATIONS

29 August 2014 - French ophthalmic company Nicox SA (EPA:COX) said Friday it had signed an exclusive deal with Japanese peer Nitto Medic for the distribution in Japan of Nicox's in-vitro diagnostic test, AdenoPlus, for the differential diagnosis of acute conjunctivitis.

As part of the accord, Nitto Medic will provide an upfront payment of EUR 500,000 (USD 659,000) to Nicox and will purchase AdenoPlus tests from the French firm. Nitto Medic will also be responsible for securing regulatory clearance for the product in Japan prior to its launch. AdenoPlus is anticipated to be introduced in the country over the next 18 months, pending regulatory licence.

Nicox holds global rights outside North America for the test under an agreement with Rapid Pathogen Screening Inc (RPS). Nicox launched AdenoPlus in France, Germany, Italy, Spain and the UK in the first half of the year and has agreements with third parties in Switzerland, Turkey, Benelux, South Africa and Poland.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:9JAPA
Date:Aug 29, 2014
Words:187
Previous Article:Agilux Laboratories undergoes space expansion of in vivo pharmacokinetics services.
Next Article:Mylan's Glatiramer Acetate Injection 40 mg/ml MS ANDA filed with the US FDA.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters